Lymphedema is the side effect people worry about most after breast cancer surgery, and often the one they understand least. It is swelling in the arm, hand or chest wall caused by disruption of the lymphatic drainage, and the single biggest factor in whether it develops is how many lymph nodes were removed from the armpit. That number is not fixed. Surgery has changed considerably over the past fifteen years, and far fewer women now need the extensive node clearance that carried the highest risk. This article explains the real risk figures, the early signs, and what modern surgery does differently.
The lymphatic system is a network of thin vessels and small nodes that drains fluid out of the tissues and returns it to the bloodstream. Most of the lymph from the arm and breast passes through nodes in the armpit, the axilla. Breast cancer surgery frequently involves removing some of those nodes to find out whether cancer has spread, and radiation therapy to the same area can scar the remaining vessels.
When enough of that drainage capacity is lost, fluid accumulates in the tissues and the arm swells. That is lymphedema, spelled lymphoedema in the UK. It is not an infection and not a sign that the cancer has returned, but it is chronic: once established it is managed rather than cured, which is precisely why prevention and early detection matter so much. The National Cancer Institute maintains a detailed summary of causes, staging and treatment.
The honest answer is that the risk depends almost entirely on what was done to your armpit, and the range is wide.
A systematic review and meta-analysis by DiSipio and colleagues in The Lancet Oncology (doi: 10.1016/S1470-2045(13)70076-7) pooled data across studies and found that roughly one in five women developed arm lymphedema after breast cancer treatment. Crucially, that average hides a large gap: the risk after a full axillary clearance was about four times higher than after a sentinel node biopsy, where only a small number of nodes are removed. Radiation to the axilla, a higher body mass index and having had an infection in the arm all increase the risk further.
The practical takeaway is that the question to ask is not "will I get lymphedema" but "how many of my lymph nodes will be removed, and will my armpit be irradiated". Those two answers largely determine where you sit in that range.
For decades, a positive sentinel node meant the whole axilla was cleared. That changed with the ACOSOG Z0011 trial, published by Giuliano and colleagues in JAMA (doi: 10.1001/jama.2011.90), which found that in selected women with early breast cancer and limited sentinel node involvement, removing the remaining nodes did not improve survival. It did, however, add complications. That single result moved the standard of care towards de-escalation: take out only what actually changes the treatment plan.
A second shift came from neoadjuvant treatment, where chemotherapy is given before surgery. Many affected nodes respond completely, so clearing the whole axilla afterwards removes healthy tissue for no benefit. The answer is targeted axillary dissection, or TAD: the involved node is marked before treatment starts, and after chemotherapy the surgeon removes that specific marked node together with the sentinel nodes, instead of all of them. Egle and colleagues at the Medical University of Innsbruck reported on marker guided TAD in Breast Care (doi: 10.1159/000541704). How the procedure works is set out in Targeted Axillary Dissection and, for the post chemotherapy setting, in Targeted Axillary Dissection After Neoadjuvant Chemotherapy.
Both shifts point the same way: fewer nodes removed, lower lymphedema risk, without giving up oncological safety. The American Cancer Society describes how the different node operations compare.
Lymphedema is far easier to control when it is caught early, and the first signs are subtle rather than dramatic swelling:
Lymphedema can appear months or even years after surgery, so these signs stay relevant long after the treatment is over. Any sudden swelling combined with redness, warmth or fever needs same day medical attention, because cellulitis in a lymphedematous arm needs prompt antibiotic treatment.
Much of the older advice about protecting the arm has been softened by evidence, and some of it was never well founded. What holds up:
Across pooled studies roughly one in five women develop it, but the figure varies enormously by procedure. After a sentinel node biopsy the risk is a few percent; after a full axillary clearance it is several times higher, and higher again when radiation to the axilla is added.
Most cases develop in the first two to three years, with the highest incidence in the first 12 to 18 months. It can also appear much later, sometimes triggered by an infection or injury to the arm, which is why the early signs remain worth knowing indefinitely.
It can usually be controlled well but not reversed. Compression garments, manual lymphatic drainage, exercise and skin care keep the swelling down and prevent progression. Treatment started early is considerably more effective than treatment started late, which is the main argument for monitoring.
It can, but far less often than a full clearance, because only a small number of nodes are removed. Some people notice temporary tightness or numbness in the armpit afterwards that settles over weeks. The procedure itself is described in Sentinel Lymph Node Dissection.
Usually not. It is a consequence of the treatment rather than the disease. That said, new or rapidly worsening swelling should always be assessed, because the same symptom occasionally has another cause.
The traditional blanket ban has been relaxed as the evidence has been re-examined, and many centers now individualize the advice rather than prohibiting it outright. Follow the guidance of your own lymphedema service, which knows your surgery and your risk profile.
Nothing. Lymphedema is the American spelling and lymphoedema the British one, for the same condition.
De-escalating axillary surgery only works if the surgeon can reliably find the specific node that needs to come out. In targeted axillary dissection, the affected node is marked before systemic treatment begins, then has to be relocated weeks or months later, often after the node has shrunk and the surrounding tissue has changed. If that node cannot be retrieved with confidence, the fallback is a wider clearance, which is exactly the outcome the approach is designed to avoid.
Sirius Medical developed the Pintuition System® to make that retrieval dependable. The Pintuition Marker® is a non radioactive, permanent magnetic marker that can be implanted long term, so it can be placed before neoadjuvant treatment and stay in position throughout. During surgery, GPSDetect™ gives the surgeon continuous distance and direction to the marker and TargetLOC™ confirms alignment, with a signal that remains accurate in blood, fluid and hematoma and is unaffected by electrocautery. Marker guided TAD after neoadjuvant systemic treatment was reported by Egle and colleagues in Breast Care (doi: 10.1159/000541704). Reliable marker retrieval is what allows a surgeon to take out one node instead of twenty, and that difference is the difference in lymphedema risk.
Learn how Pintuition® can support precision, workflow efficiency and reliable excision in breast cancer surgery. Request demo or explore the clinical overview for more information.
Disclaimer
This article is intended for informational purposes only and should not be considered medical advice. Clinical decisions should always be made by qualified healthcare professionals based on individual patient needs and current guidelines.